| Quarter (USD) | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 82.47 mm | 82.47 mm | 82.47 mm | 82.47 mm | 82.47 mm | 82.47 mm |
| Cash burn (monthly) | 5.72 mm | (no burn) | 34.06 mm | 36.03 mm | 22.19 mm | 22.27 mm |
| Cash used (since last report) | 13.14 mm | n/a | 78.26 mm | 82.78 mm | 50.97 mm | 51.16 mm |
| Cash remaining | 69.33 mm | n/a | 4.21 mm | -308.63 k | 31.50 mm | 31.32 mm |
| Runway (months of cash) | 12.1 | n/a | 0.1 | -0.0 | 1.4 | 1.4 |
| 13F holders | Current |
|---|---|
| Total holders | 179 |
| Opened positions | 25 |
| Closed positions | 23 |
| Increased positions | 50 |
| Reduced positions | 59 |
| 13F shares | Current |
|---|---|
| Total value | 263.06 bn |
| Total shares | 61.92 mm |
| Total puts | 117.00 k |
| Total calls | 266.20 k |
| Total put/call ratio | 0.4 |
| Largest owners | Shares | Value |
|---|---|---|
| BIIB Biogen | 6.24 mm | $539.95 mm |
| BlackRock | 4.85 mm | $26.34 bn |
| Vanguard | 4.84 mm | $26.27 bn |
| MS Morgan Stanley | 4.59 mm | $24.95 bn |
| BBBOF BB Biotech | 4.46 mm | $28.73 mm |
| BLVGF Bellevue | 4.46 mm | $24.22 bn |
| FMR | 4.12 mm | $22.36 bn |
| Caligan Partners | 3.05 mm | $16.58 bn |
| RTW Investments | 3.00 mm | $16.30 bn |
| Millennium Management | 1.62 mm | $8.82 bn |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 24 Feb 25 | Gregory L. Shiferman | Common Stock | Payment of exercise | Dispose F | No | No | 7.49 | 2,502 | 18.74 k | 30,759 |
| 13 Feb 25 | Christopher Benecchi | Common Stock | Payment of exercise | Dispose F | No | No | 7.18 | 822 | 5.90 k | 43,915 |
| 13 Feb 25 | Laura Gault | Common Stock | Payment of exercise | Dispose F | No | No | 7.18 | 685 | 4.92 k | 34,649 |
| 13 Feb 25 | Gregory L. Shiferman | Common Stock | Payment of exercise | Dispose F | No | No | 7.18 | 251 | 1.80 k | 33,261 |
| 13 Feb 25 | Gregory L. Shiferman | Common Stock | Payment of exercise | Dispose F | No | No | 7.18 | 376 | 2.70 k | 33,512 |
| 16 Jan 25 | Laura Gault | Common Stock | Grant | Acquire A | No | No | 0 | 24,000 | 0.00 | 35,334 |
